^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ONCR-788
i
Other names: ONCR-788, Seneca Valley Virus (SVV)-based synthetic virus program
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Oncorus
Drug class:
Immunostimulant
Related drugs:
2years
Overcoming the Challenge of RNA Therapeutics for the Treatment of Cancer, Development of Lipid Nanoparticle-Formulated RNA Viral Immunotherapy (ASGCT 2022)
Interestingly, the in vivo efficacy of ONCR-021 and ONCR-788 is maintained even in the presence of neutralizing antibodies against CVA21 and SVV, suggesting that administration of LNP-formulated RNA immunotherapy enables the repeated and systemic exposure of disseminated tumors to potently oncolytic viruses. These data highlight an innovative RNA therapeutic modality for the IV treatment of tumors which overcomes the limitations of other RNA-based therapeutics and supports ONCR-021 and ONCR-788 into IND-enabling studies.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Cavatak (gebasaxturev) • ONCR-021 • ONCR-788
2years
Development of ONCR-788, a synthetic oncolytic virus based on Seneca Valley virus for the treatment of neuroendocrine tumors (AACR 2022)
Combination of ONCR-788 with anti-PD-1 resulted in improved anti-tumor activity versus the monotherapy arms. Altogether, ONCR-788 provides an innovative approach that enables repeat intravenous administration of viral immunotherapy.
Oncolytic virus • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
ONCR-788
Share via
